MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$1,999,397
EPS
-$0.05
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2025-12-31
2025-09-30
2025-06-30
Research and development
1,164,737
809,991
1,074,985.25*
General and administrative
1,455,173
1,450,269
1,230,885*
Total operating expenses
2,619,910
2,260,260
2,305,870.25
Loss from operations
-2,619,910
-2,260,260
-2,305,870.25*
Interest expense
17,439
17,439
95,503.5*
Interest income
85,410
109,616
64,478.25*
Grant income
552,576
9,825
216,003.5*
Other
-34
-96
-298.75*
Other income, net
620,513
101,906
184,679.5*
Net loss
-1,999,397
-2,158,354
-2,121,190.75
Basic EPS
-0.05
-0.05
-0.063
Diluted EPS
-0.05
-0.05
-0.063
Basic Average Shares
41,084,731
41,084,731
33,820,306
Diluted Average Shares
41,084,731
41,084,731
33,820,306
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Grant income
$552,576
Interest income
$85,410
Net loss
-$1,999,397
Other income, net
$620,513
Interest expense
$17,439
Other
-$34
Loss from operations
-$2,619,910
Total operating
expenses
$2,619,910
General and
administrative
$1,455,173
Research and development
$1,164,737
Buy us a coffee
Anebulo Pharmaceuticals, Inc. (ANEB)
Anebulo Pharmaceuticals, Inc. (ANEB)